Novanta Acquires Riverpoint Medical for $1.45B to Expand Minimally Invasive Surgery Portfolio
NOVT sits 67% above its 52-week low of $98.27.
Summary
Novanta Inc. is acquiring Riverpoint Medical for $1.45 billion to significantly expand its medical consumables business, financed partly by a recent $300 million equity raise, with expectations for immediate accretion to earnings and long-term growth.
Key Events · M&A and Partnerships · NOVT
-
Strategic Acquisition Announced
Novanta Inc. will acquire Riverpoint Medical for a total consideration of $1.45 billion, consisting of $1.2 billion upfront cash and a $250 million milestone payment due by January 8, 2027.
-
Financing Details
The acquisition is financed through a combination of cash on hand, existing credit facilities, and a recently completed $300 million equity raise.
-
Credit Facility Amendments
The company amended its credit agreement, widening the interest rate pricing margin by 0.25% if the consolidated leverage ratio exceeds 3.75:1.00 and increasing the permitted consolidated leverage ratio to 4.00:1.00 (or 4.50:1.00 for four quarters following a Designated Acquisition) to accommodate the acquisition-related debt.
-
Expected Financial Impact
Novanta anticipates the acquisition to be immediately accretive to Adjusted Diluted EPS in 2026 and to revenue growth, Adjusted Gross and EBITDA margins, and Operating Cash Flows in 2027.
Analysis · NOVT · Manufacturing
Novanta Inc. is making a significant strategic move by acquiring Riverpoint Medical for an upfront cash payment of $1.2 billion and a $250 million milestone payment, totaling $1.45 billion. This acquisition, representing approximately 25% of Novanta's market capitalization, is aimed at accelerating its shift towards recurring medical consumables revenue and expanding into high-growth minimally invasive surgery segments. The transaction is financed through a combination of cash on hand, existing credit facilities, and a recently completed $300 million equity raise. While the equity raise is dilutive, the company expects the acquisition to be immediately accretive to Adjusted Diluted EPS in 2026 and to revenue growth, margins, and cash flows in 2027. The company also amended its credit agreement to accommodate increased leverage, reflecting the substantial debt taken on for this acquisition.
At the time of this filing, NOVT was trading at $164.34 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $5.9B. The 52-week trading range was $98.27 to $171.85. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.